[1] WGO(World Gastroenterolopy Organiastion). World gastroenterolopy organiastion global guidelines nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol,2014,48:467-473.
[2] Duan XY,Zhang L,Fan JG,et al.NAFLD leads to liver cancer:do we have sufficient evidence.Cancer let,2014,345:230-234.
[3] Nascimbeni F,Pais R,Bellen-Tani S,et al.Form NAFLD in clinical practice to answers from guidelines.J Hepatol,2013,59:859-871.
[4] Bruix J, Sherman M. Management of hepatocellular carcinoma.Hepatology,2005,42:1208-1236.
[5] Leite NC, Salles GF, Araujo AL,et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int, 2009, 29:113-119.
[6] McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis,2004, 8:521-533, viii.
[7] Ascha MS, Hanouneh IA, Lopez R,et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology,2010, 51:1972-1978.
[8] Rosmorduc O, Relationship between hepatocellular carcinoma, metabolic syndrome and non-alchholic fatty liver disease :Which clinical arguments.Ann Endocrinol(Paris),2013,74: 115-120.
[9] Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.Hepatology,2010,51:1820-1832.
[10] Bugianesi E, Leone N, Vanni E,et al.Expanding the natural history of nonalcoholic steatohepatitis:from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology,2002, 123:134-140.
[11] Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. Hepatology, 2014, 59:2188-2195.
[12] Ong J, Younossi ZM, Reddy V,et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl,2001,7:797-801.
[13] Yasui K, Hashimoto E, Tokushige K,et al. Clinical and pathological progression of nonalcoholic steatohepatitis to hepatocellular carcinoma. Hepatol Res,2012, 42: 767-773.
[14] Rinella ME.Nonalcoholic fatty disease:asystematic review.JAMA, 2015,313:2263-2273.
[15] Byrne CD,Targher G.NAFLD:A multisystem disease.J Hepatol, 2015,62:s47-s65.
[16] Alexander J, Torbenson M, Wu TT, et al. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J Gastroenterol Hepatol,2013,28: 848-854.
[17] Ertle J, Dechêne A, Sowa JP, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer,2011,128: 2436-2443.
[18] Leung C,Yeoh SW,Patrick D,et al.Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease.World J Gastroenterol,2015,21:1189-1196.
[19] Calle EE, Rodriguez C, Walker-Thurmond K, et al.Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med,2003,348: 1625-1638.
[20] Noureddin M, Rinella ME.Nonalcoholic fatty liver disease, diabetes,obesity,and hepatocellular carcinoma.Clin Liver Dis,2015,19:361-379.
[21] Ohki T, Tateishi R, Shiina S, et al. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut,2009, 58: 839-844.
[22] 巫协宁,陆伦根.非酒精性脂肪性肝炎肝纤维化的发生机制及其诊断的生物标志.肝脏,2014,19:629-631.
[23] Chen C,Chang YC,Liu CL,et al.Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway.Endocr Relat Cancer,2007,14:513-529.
[24] Raff EJ,Kakati D,Bloomer JR,et al.Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and non-alcholic fatty liver disease.J Clin Transl Hepatol,2015,3:9-16.
[25] Torres DM,Harrison SA.Nonalcoholic steatohepatitis andnoncirrhotic hepatocellular carcinoma:fertile soil.Semin Liver Dis,2012,32:30-38.
[26] Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications.Gut,2010, 59: 1303-1307.
[27] Marra F. Leptin and liver fibrosis: a matter of fat. Gastroenterology, 2002, 122: 1529-1532.
[28] 巫协宁.非酒精性脂肪性肝炎肝细胞癌的发病机制.中华消化杂志,2015,35:77-79.
[29] Chang Q, Zhang Y, Beezhold KJ,et al. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol,2009,50: 323-333.
[30] Sorrentino P, D′Angelo S, Ferbo U, et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol, 2009,50: 351-357.
[31] Sun WL,Cao HX,Fan JG.diagnosis and treatment of non-alcoholic fatty liver disease.Chin J Hepatol,2014,22:705-707. |
